AveXis (NASDAQ:AVXS) has been assigned a $132.00 price objective by research analysts at Citigroup in a report released on Friday. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 29.31% from the stock’s previous close.
Several other research analysts have also recently issued reports on the stock. Canaccord Genuity set a $110.00 target price on shares of AveXis and gave the company a “hold” rating in a report on Wednesday, December 20th. BidaskClub upgraded shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. ValuEngine cut shares of AveXis from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Bank of America lowered their target price on shares of AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a report on Friday, November 10th. Finally, Royal Bank of Canada upped their target price on shares of AveXis from $92.00 to $97.00 and gave the company a “sector perform” rating in a report on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $111.94.
AveXis (NASDAQ AVXS) traded down $2.66 during midday trading on Friday, reaching $102.08. 837,632 shares of the company’s stock traded hands, compared to its average volume of 367,840. AveXis has a 12 month low of $50.56 and a 12 month high of $116.15.
In related news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total transaction of $180,242.80. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at approximately $180,242.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now owns 7,000 shares of the company’s stock, valued at approximately $661,360. The disclosure for this sale can be found here. In the last quarter, insiders have sold 67,340 shares of company stock valued at $6,840,745. 18.60% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the stock. Strs Ohio acquired a new stake in AveXis during the 3rd quarter worth $116,000. Ameritas Investment Partners Inc. boosted its stake in AveXis by 331.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after purchasing an additional 1,622 shares during the period. Cubist Systematic Strategies LLC boosted its stake in AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares during the period. Teacher Retirement System of Texas acquired a new stake in AveXis during the 3rd quarter worth $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in AveXis during the 3rd quarter worth $203,000. Hedge funds and other institutional investors own 92.88% of the company’s stock.
TRADEMARK VIOLATION WARNING: “AveXis (AVXS) Given a $132.00 Price Target by Citigroup Analysts” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2018/01/07/avexis-avxs-given-a-132-00-price-target-by-citigroup-analysts.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
What are top analysts saying about AveXis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AveXis and related companies.